Inogen Inc (NASDAQ:INGN) EVP Brenton Taylor sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $259.42, for a total transaction of $1,297,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Brenton Taylor also recently made the following trade(s):

  • On Wednesday, August 1st, Brenton Taylor sold 5,000 shares of Inogen stock. The stock was sold at an average price of $197.80, for a total transaction of $989,000.00.
  • On Monday, July 2nd, Brenton Taylor sold 5,000 shares of Inogen stock. The stock was sold at an average price of $184.40, for a total transaction of $922,000.00.

Shares of INGN opened at $263.85 on Friday. Inogen Inc has a 12 month low of $91.80 and a 12 month high of $267.85. The firm has a market cap of $5.54 billion, a PE ratio of 201.41, a price-to-earnings-growth ratio of 5.14 and a beta of 1.24.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, August 7th. The medical technology company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.21. Inogen had a net margin of 10.39% and a return on equity of 16.51%. The company had revenue of $97.24 million for the quarter, compared to analyst estimates of $81.61 million. research analysts forecast that Inogen Inc will post 2.06 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in INGN. Catalyst Capital Advisors LLC acquired a new position in shares of Inogen during the 2nd quarter worth $112,000. Advisors Preferred LLC acquired a new position in shares of Inogen during the 2nd quarter worth $176,000. SG Americas Securities LLC acquired a new position in shares of Inogen during the 1st quarter worth $178,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of Inogen during the 2nd quarter worth $186,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in shares of Inogen during the 2nd quarter worth $216,000. Institutional investors own 97.06% of the company’s stock.

INGN has been the subject of a number of research analyst reports. Piper Jaffray Companies increased their target price on shares of Inogen to $235.00 and gave the stock an “overweight” rating in a research report on Monday, July 9th. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 7th. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “strong-buy” rating and set a $232.00 target price for the company in a research report on Wednesday, July 11th. Needham & Company LLC increased their target price on shares of Inogen from $215.00 to $254.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, August 8th. Finally, Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the stock a “buy” rating in a research report on Tuesday, August 21st. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Inogen presently has an average rating of “Buy” and a consensus target price of $230.50.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Article: What is a Tariff?

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.